CapsoVision, Inc
Business
CapsoVision is a medical-device manufacturer that develops and commercializes capsule endoscopy solutions for diagnostic imaging of the gastrointestinal tract. The company's primary product, CapsoCam Plus, is an FDA-cleared single-use ingestible capsule for small-bowel visualization, supported by cloud-based and desktop software platforms for video review and data management. The company also markets CapsoCam Colon, a pipeline product in clinical development for colon polyp detection. CapsoVision sells directly to gastroenterologists and hospitals in the U.S. and through distributors internationally.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Net revenue | 14 | 12 | |
| Costs of revenue | 6 | 5 | |
| Gross profit | 7 | 6 | |
| Selling and marketing | 8 | 7 | |
| Research and development | 18 | 15 | |
| General and administrative | 7 | 4 | |
| Total operating expenses | 33 | 26 | |
| Operating loss | −26 | −20 | |
| Interest income, net | 269,000 | 26,000 | |
| Other non-operating income (expense), net | −44,000 | 4,000 | |
| Total non-operating income, net | 225,000 | 30,000 | |
| Loss before income taxes | −25 | −20 | |
| Provision for income taxes | 24,000 | 11,000 | |
| Net loss | −25 | −20 | |
| Net loss per share - basic (in dollars per share) | −1.03 | −9.85 | |
| Net loss per share - diluted (in dollars per share) | −1.03 | −9.85 | |
| Weighted-average common shares outstanding - basic (in shares) | 25 | 2 | |
| Weighted-average common shares outstanding - diluted (in shares) | 25 | 2 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 10 | 9 | — | |
| Accounts receivable, net | 2 | 2 | — | |
| Inventory | 3 | 3 | — | |
| Prepaid expenses and other current assets | 1 | 898,000 | — | |
| Total current assets | 17 | 15 | — | |
| Property and equipment, net | 611,000 | 720,000 | — | |
| Operating lease right-of-use assets | 843,000 | 1 | — | |
| Other long-term assets | 41,000 | 41,000 | — | |
| TOTAL ASSETS | 18 | 17 | — | |
| Accounts payable | 1 | 749,000 | — | |
| Accrued expenses and other current liabilities | 3 | 569,000 | — | |
| Deferred revenue | 177,000 | 132,000 | 96,000 | |
| Operating lease liabilities - current | 410,000 | 351,000 | — | |
| Total current liabilities | 4 | 2 | — | |
| Operating lease liabilities long-term | 477,000 | 887,000 | — | |
| Total liabilities | 5 | 3 | — | |
| Commitments and contingencies - Note 9 | — | — | — | |
| Total convertible preferred stock | 0 | 144 | 129 | |
| Common stock, $0.001 par value: 300,000,000 and 190,000,000 shares authorized; 46,865,051 and 2,090,945 issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 47,000 | 2,000 | — | |
| Additional paid-in capital | 169 | 838,000 | — | |
| Accumulated deficit | −156 | −130 | — | |
| Total stockholders equity (deficit) | 13 | −130 | −110 | |
| TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS EQUITY (DEFICIT) | 18 | 17 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Depreciation and amortization | 216,000 | 206,000 | |
| Loss on disposal of property and equipment | 1,000 | 0 | |
| Amortization of operating lease right-of-use assets | 351,000 | 315,000 | |
| Unrealized foreign exchange (gains) losses | −173,000 | 103,000 | |
| Stock in lieu of debt repayment | 31,000 | 0 | |
| Stock-based compensation | 826,000 | 156,000 | |
| Bad debt expense | 11,000 | 8,000 | |
| Accounts receivable | −478,000 | −176,000 | |
| Inventory | −358,000 | −434,000 | |
| Prepaid expenses and other current assets | −174,000 | −316,000 | |
| Other long-term assets | 0 | 1,000 | |
| Accounts payable | 376,000 | 388,000 | |
| Accrued expenses and other current liabilities | 2 | −204,000 | |
| Deferred revenue | 45,000 | 36,000 | |
| Operating lease liabilities | −351,000 | −276,000 | |
| Net cash used in operating activities | −23 | −20 | |
| Purchases of property and equipment | −90,000 | −153,000 | |
| Net cash used in investing activities | −90,000 | −153,000 | |
| Proceeds from issuance of Series H convertible preferred stock | 0 | 15 | |
| Proceeds from IPO, net of commissions | 27 | 0 | |
| Payment of IPO offering costs | −3 | 0 | |
| Proceeds from promissory note issuance | 1 | 0 | |
| Repayment of promissory note | −1 | 0 | |
| Proceeds from exercises of options on common stock and warrants | 231,000 | 74,000 | |
| Net cash provided by financing activities | 24 | 15 | |
| Net increase (decrease) in cash and cash equivalents | 650,000 | −5 | |
| Effect of exchange rate changes on cash and cash equivalents | 143,000 | −70,000 | |
| Cash paid for income taxes | 9,000 | 6,000 | |
| Cash paid for interest | 15,000 | 0 | |
| Underwriters warrants issued in connection with the IPO | 519,000 | 0 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is CapsoVision, Inc's CIK number?
CapsoVision, Inc's SEC CIK number is 0001378325 (1378325). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find CapsoVision, Inc's SEC filings?
All of CapsoVision, Inc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did CapsoVision, Inc last report earnings?
CapsoVision, Inc (CV) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001378325-26-000019). This is CapsoVision, Inc's most recent earnings filing of record — not a forecast of its next earnings date.
What is CapsoVision, Inc's most recent earnings 8-K?
CapsoVision, Inc's latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001378325-26-000019. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View CapsoVision, Inc's latest earnings 8-K →
Look up any company's CIK number →